Genomic and Transcriptional Landscape of P2RY8-CRLF2-positive Childhood Acute Lymphoblastic Leukemia
Overview
Authors
Affiliations
Children with P2RY8-CRLF2-positive acute lymphoblastic leukemia have an increased relapse risk. Their mutational and transcriptional landscape, as well as the respective patterns at relapse remain largely elusive. We, therefore, performed an integrated analysis of whole-exome and RNA sequencing in 41 major clone fusion-positive cases including 19 matched diagnosis/relapse pairs. We detected a variety of frequently subclonal and highly instable JAK/STAT but also RTK/Ras pathway-activating mutations in 76% of cases at diagnosis and virtually all relapses. Unlike P2RY8-CRLF2 that was lost in 32% of relapses, all other genomic alterations affecting lymphoid development (58%) and cell cycle (39%) remained stable. Only IKZF1 alterations predominated in relapsing cases (P=0.001) and increased from initially 36 to 58% in matched cases. IKZF1's critical role is further corroborated by its specific transcriptional signature comprising stem cell features with signs of impaired lymphoid differentiation, enhanced focal adhesion, activated hypoxia pathway, deregulated cell cycle and increased drug resistance. Our findings support the notion that P2RY8-CRLF2 is dispensable for relapse development and instead highlight the prominent rank of IKZF1 for relapse development by mediating self-renewal and homing to the bone marrow niche. Consequently, reverting aberrant IKAROS signaling or its disparate programs emerges as an attractive potential treatment option in these leukemias.
Non-histone lactylation: unveiling its functional significance.
Shi P, Ma Y, Zhang S Front Cell Dev Biol. 2025; 13:1535611.
PMID: 39925738 PMC: 11802821. DOI: 10.3389/fcell.2025.1535611.
Secondary lesions and sensitivity to signaling inhibitors in iAMP21 acute lymphoblastic leukemia.
Hormann F, Ostergaard A, van den Broek S, Boeree A, van de Ven C, Escherich G Hemasphere. 2025; 9(1):e70069.
PMID: 39840380 PMC: 11746935. DOI: 10.1002/hem3.70069.
He G, Lei Y, Huang D, Gao J, Yang R BMC Pediatr. 2024; 24(1):517.
PMID: 39127642 PMC: 11316372. DOI: 10.1186/s12887-024-04991-w.
Mohd Nippah N, Abu N, Ab Mutalib N, Alias H Front Genet. 2024; 15:1394523.
PMID: 38894724 PMC: 11183504. DOI: 10.3389/fgene.2024.1394523.
Gil J, Miralles A, de Las Heras S, Such E, Avetisyan G, Diaz-Gonzalez A Front Mol Biosci. 2024; 11:1362081.
PMID: 38370004 PMC: 10869515. DOI: 10.3389/fmolb.2024.1362081.